| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Kimmel Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania 19107
We have investigated the ability of several drugs commonly used in the treatment of human cancer to induce bcl2 phosphorylation and cell death in human cell lines derived from acute leukemia, lymphoma, breast cancer, and prostate cancer. The results of this analysis indicate that drugs affecting the integrity of microtubules induce bcl2 phosphorylation, whereas anticancer drugs damaging DNA do not. Comparison of the effects of taxol and its analogue, taxotere, indicates that taxotere is capable of inducing bcl2 phosphorylation and apoptotic cell death at 100-fold lower concentrations than taxol. Induction of cancer cell death through phosphorylation of bcl2 thus provides an opportunity not only for more refined targeting of therapeutic drugs but for understanding of an important pathway leading to apoptosis.
Phosphorylation of bcl2 in drug-treated cancer cells occurs in G2-M, the phase of the cell cycle in which this class of drugs is active. No induction of bcl2 phosphorylation occurs in chronic lymphocytic leukemia cells that overexpress bcl2 but are blocked at G0-G1. Thus, prevention of polymerization or depolymerization of cellular microtubules by this class of cancer therapeutic drugs causes phosphorylation of bcl2, abrogating the normal antiapoptotic function of bcl2 and initiating the apoptotic program in the cycling cancer cells; these results are consistent with a normal physiological role of bcl2 as "guardian of microtubule integrity."
1 Supported by the Council for Tobacco Research Grant 3496A (to S. H.) and National Cancer Institute Grant CA39860 (to C. M. C.).
2 To whom requests for reprints should be addressed, at Kimmel Cancer Center, Bluemle Life Sciences Building, Rm. 1032, 233 South 10th Street, Philadelphia, PA 19107-5799.
Received 12/ 2/96. Accepted 12/23/96.
This article has been cited by other articles:
|
|
 |
|
  N. J. Sanfilippo, S. S. Taneja, A. Chachoua, H. Lepor, and S. C. Formenti Phase I/II Study of Biweekly Paclitaxel and Radiation in Androgen-Ablated Locally Advanced Prostate Cancer J. Clin. Oncol., June 20, 2008; 26(18): 2973 - 2978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Mooberry, K. N. Weiderhold, S. Dakshanamurthy, E. Hamel, E. J. Banner, A. Kharlamova, J. Hempel, J. T. Gupton, and M. L. Brown Identification and Characterization of a New Tubulin-Binding Tetrasubstituted Brominated Pyrrole Mol. Pharmacol., July 1, 2007; 72(1): 132 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Shajahan, A. Wang, M. Decker, R. D. Minshall, M. C. Liu, and R. Clarke Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity J. Biol. Chem., February 23, 2007; 282(8): 5934 - 5943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Lin, H.-K. Chang, J.-S. Chen, H.-M. Wang, T.-S. Yang, and C.-C. Liaw A Phase II Randomized Study of Two Taxanes and Cisplatin for Metastatic Breast Cancer after Anthracycline: A Final Analysis Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 23 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A. Esteve, M. Carre, V. Bourgarel-Rey, A. Kruczynski, G. Raspaglio, C. Ferlini, and D. Braguer Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol. Cancer Ther., November 1, 2006; 5(11): 2824 - 2833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yoshino, H. Shiina, S. Urakami, N. Kikuno, T. Yoneda, K. Shigeno, and M. Igawa Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin. Cancer Res., October 15, 2006; 12(20): 6116 - 6124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Wood, L. M. Nail, N. A. Perrin, C. R. Elsea, A. Fischer, and B. J. Druker The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior-like Symptoms in a Mouse Model of Cancer Chemotherapy-Related Symptoms. Biol Res Nurs, October 1, 2006; 8(2): 157 - 169. [Abstract] [PDF]
|
|
|
|
|
|
A. D. Colevas Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., June 10, 2006; 24(17): 2644 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tesfaigzi Roles of Apoptosis in Airway Epithelia Am. J. Respir. Cell Mol. Biol., May 1, 2006; 34(5): 537 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Messersmith, S. D. Baker, L. Lassiter, R. A. Sullivan, K. Dinh, V. I. Almuete, J. J. Wright, R. C. Donehower, M. A. Carducci, and D. K. Armstrong Phase I Trial of Bortezomib in Combination with Docetaxel in Patients with Advanced Solid Tumors Clin. Cancer Res., February 15, 2006; 12(4): 1270 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Morse, H. Gray, C. M. Payne, and R. J. Gillies Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells Mol. Cancer Ther., October 1, 2005; 4(10): 1495 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tabuchi, H. To, H. Sakaguchi, N. Goto, A. Takeuchi, S. Higuchi, and S. Ohdo Therapeutic Index by Combination of Adriamycin and Docetaxel Depends on Dosing Time in Mice Cancer Res., September 15, 2005; 65(18): 8448 - 8454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W.J. Urba, K.I. Pritchard, et al. Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer J. Clin. Oncol., August 20, 2005; 23(24): 5542 - 5551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L A Emens, R T Reilly, and E M Jaffee Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takahashi, M. Suzuki, H. Kume, S. Matsumoto, N. Okamoto, H. Nishimatsu, K. Tomita, and T. Kitamura Combination Chemotherapy of Docetaxel, Ifosfamide and Cisplatin (DIP) in Patients with Metastatic Urothelial Cancer: a Preliminary Report Jpn. J. Clin. Oncol., February 1, 2005; 35(2): 79 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gu, L. Espana, O. Mendez, A. Torregrosa, and A. Sierra Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus Carcinogenesis, December 1, 2004; 25(12): 2293 - 2301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Pourroy, M. Carre, S. Honore, V. Bourgarel-Rey, A. Kruczynski, C. Briand, and D. Braguer Low Concentrations of Vinflunine Induce Apoptosis in Human SK-N-SH Neuroblastoma Cells through a Postmitotic G1 Arrest and a Mitochondrial Pathway Mol. Pharmacol., September 1, 2004; 66(3): 580 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kuznetsov, M. J. Towle, H. Cheng, T. Kawamura, K. TenDyke, D. Liu, Y. Kishi, M. J. Yu, and B. A. Littlefield Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389 Cancer Res., August 15, 2004; 64(16): 5760 - 5766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Marshall, H. Chen, D. Yang, M. Figueira, K. B. Bouker, Y. Ling, M. Lippman, S. R. Frankel, and D. F. Hayes A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors Ann. Onc., August 1, 2004; 15(8): 1274 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Dahut, J. L. Gulley, P. M. Arlen, Y. Liu, K. M. Fedenko, S. M. Steinberg, J. J. Wright, H. Parnes, C. C. Chen, E. Jones, et al. Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer J. Clin. Oncol., July 1, 2004; 22(13): 2532 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Kuo, H.-P. Hsieh, W.-Y. Pan, C.-P. Chen, J.-P. Liou, S.-J. Lee, Y.-L. Chang, L.-T. Chen, C.-T. Chen, and J.-Y. Chang BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo Cancer Res., July 1, 2004; 64(13): 4621 - 4628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gligorov and J. P. Lotz Preclinical Pharmacology of the Taxanes: Implications of the Differences Oncologist, June 2, 2004; 9(suppl_2): 3 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 739 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. To, M. Shin, M. Tabuchi, H. Sakaguchi, A. Takeuchi, N. Matsunaga, S. Higuchi, and S. Ohdo Influence of Dosing Schedule on Toxicity and Antitumor Effects of a Combination of Adriamycin and Docetaxel in Mice Clin. Cancer Res., January 15, 2004; 10(2): 762 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Masuda, K. Maeno, T. Nakagawa, H. Saito, and T. Takahashi Association between Mitotic Spindle Checkpoint Impairment and Susceptibility to the Induction of Apoptosis by Anti-Microtubule Agents in Human Lung Cancers Am. J. Pathol., September 1, 2003; 163(3): 1109 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Tinley, D. A. Randall-Hlubek, R. M. Leal, E. M. Jackson, J. W. Cessac, J. C. Quada Jr., T. K. Hemscheidt, and S. L. Mooberry Taccalonolides E and A: Plant-derived Steroids with Microtubule-stabilizing Activity Cancer Res., June 15, 2003; 63(12): 3211 - 3220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Motwani, C. Rizzo, F. Sirotnak, Y. She, and G. K. Schwartz Flavopiridol Enhances the Effect of Docetaxel in Vitro and in Vivo in Human Gastric Cancer Cells Mol. Cancer Ther., June 1, 2003; 2(6): 549 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shimada, M. Nakamura, E. Ishida, M. Kishi, and N. Konishi Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis Carcinogenesis, June 1, 2003; 24(6): 1067 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Tinley, R. M. Leal, D. A. Randall-Hlubek, J. W. Cessac, L. R. Wilkens, P. N. Rao, and S. L. Mooberry Novel 2-Methoxyestradiol Analogues with Antitumor Activity Cancer Res., April 1, 2003; 63(7): 1538 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. van de Wouw, R. L. H. Jansen, E. J. M. Speel, and H. F. P. Hillen The unknown biology of the unknown primary tumour: a literature review Ann. Onc., February 1, 2003; 14(2): 191 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ravandi, M. Talpaz, and Z. Estrov Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Yoo, M. P. Piechocki, J. F. Ensley, T. Nguyen, J. Oliver, H. Meng, D. Kewson, T. Y. Shibuya, F. Lonardo, and M. A. Tainsky Docetaxel Induced Gene Expression Patterns in Head and Neck Squamous Cell Carcinoma Using cDNA Microarray and PowerBlot Clin. Cancer Res., December 1, 2002; 8(12): 3910 - 3921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-i. Sasaki, R. Ramesh, S. Chada, Y. Gomyo, J. A. Roth, and T. Mukhopadhyay The Anthelmintic Drug Mebendazole Induces Mitotic Arrest and Apoptosis by Depolymerizing Tubulin in Non-Small Cell Lung Cancer Cells Mol. Cancer Ther., November 1, 2002; 1(13): 1201 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ben-Bassat, Z. Hartzstark, R. Levitzki, B. Y. Klein, Z. Shlomai, A. Gazit, and A. Levitzki Tyrosine Kinase Inhibitors Suppress the Growth of Non-Hodgkin B Lymphomas J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 163 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mabuchi, M. Ohmichi, A. Kimura, K. Hisamoto, J. Hayakawa, Y. Nishio, K. Adachi, K. Takahashi, E. Arimoto-Ishida, Y. Nakatsuji, et al. Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel J. Biol. Chem., August 30, 2002; 277(36): 33490 - 33500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kaluzhny, G. Yu, S. Sun, P. A. Toselli, B. Nieswandt, C. W. Jackson, and K. Ravid BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation Blood, August 13, 2002; 100(5): 1670 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Burke, S. J. DeNardo, L. A. Miers, K. R. Lamborn, S. Matzku, and G. L. DeNardo Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts Cancer Res., August 1, 2002; 62(15): 4263 - 4272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goodin, K. V. Rao, and R. S. DiPaola State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer Oncologist, August 1, 2002; 7(4): 360 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Piechocki, F. Lonardo, J. F. Ensley, T. Nguyen, H. Kim, and G. H. Yoo Anticancer Activity of Docetaxel in Murine Salivary Gland Carcinoma Clin. Cancer Res., March 1, 2002; 8(3): 870 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Kidd, M. F. Pilkington, M. J. Schell, K. E. Fogarty, J. N. Skepper, C. W. Taylor, and P. Thorn Paclitaxel Affects Cytosolic Calcium Signals by Opening the Mitochondrial Permeability Transition Pore J. Biol. Chem., February 15, 2002; 277(8): 6504 - 6510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Paul, F. Manero, S. Gonin, C. Kretz-Remy, S. Virot, and A.-P. Arrigo Hsp27 as a Negative Regulator of Cytochrome c Release Mol. Cell. Biol., February 1, 2002; 22(3): 816 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Coleman, Z. A. Stewart, T. A. Day, J. L. Netterville, B. B. Burkey, and J. A. Pietenpol Analysis of Cell-Cycle Checkpoint Pathways in Head and Neck Cancer Cell Lines: Implications for Therapeutic Strategies Arch Otolaryngol Head Neck Surg, February 1, 2002; 128(2): 167 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Konopleva, T. Tsao, P. Ruvolo, I. Stiouf, Z. Estrov, C. E. Leysath, S. Zhao, D. Harris, S. Chang, C. E. Jackson, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia Blood, January 1, 2002; 99(1): 326 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Holstein and R. J. Hohl Synergistic Interaction of Lovastatin and Paclitaxel in Human Cancer Cells Mol. Cancer Ther., December 1, 2001; 1(2): 141 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Chi, M. E. Gleave, R. Klasa, N. Murray, C. Bryce, D. E. Lopes de Menezes, S. D'Aloisio, and A. W. Tolcher A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer Clin. Cancer Res., December 1, 2001; 7(12): 3920 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Flusberg, Y. Numaguchi, and D. E. Ingber Cooperative Control of Akt Phosphorylation, bcl-2 Expression, and Apoptosis by Cytoskeletal Microfilaments and Microtubules in Capillary Endothelial Cells Mol. Biol. Cell, October 1, 2001; 12(10): 3087 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. A. Figueroa-Masot, M. Hetman, M. J. Higgins, N. Kokot, and Z. Xia Taxol Induces Apoptosis in Cortical Neurons by a Mechanism Independent of Bcl-2 Phosphorylation J. Neurosci., July 1, 2001; 21(13): 4657 - 4667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond Oncologist, April 1, 2001; 6(2): 133 - 146. [Abstract] [Full Text]
|
|
|
|
|
|
S. R. White, P. Williams, K. R. Wojcik, S. Sun, P. S. Hiemstra, K. F. Rabe, and D. R. Dorscheid Initiation of Apoptosis by Actin Cytoskeletal Derangement in Human Airway Epithelial Cells Am. J. Respir. Cell Mol. Biol., March 1, 2001; 24(3): 282 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Vaishampayan, M. Glode, W. Du, A. Kraft, G. Hudes, J. Wright, and M. Hussain Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma Clin. Cancer Res., November 1, 2000; 6(11): 4205 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zeng, Y. Z. Chen, L. Fu, K. R. Johnson, and W. Fan In Vitro Evaluation of Schedule-dependent Interactions between Docetaxel and Doxorubicin against Human Breast and Ovarian Cancer Cells Clin. Cancer Res., September 1, 2000; 6(9): 3766 - 3773. [Abstract] [Full Text]
|
|
|
|
|
|
C. F. Verschraegen, T. Sittisomwong, A. P. Kudelka, E. d. P. Guedes, M. Steger, T. Nelson-Taylor, M. Vincent, R. Rogers, E. N. Atkinson, and J. J. Kavanagh Docetaxel for Patients With Paclitaxel-Resistant Mullerian Carcinoma J. Clin. Oncol., July 14, 2000; 18(14): 2733 - 2739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Blagosklonny, P. C. Bishop, R. Robey, T. Fojo, and S. E. Bates Loss of Cell Cycle Control Allows Selective Microtubule-active Drug-induced Bcl-2 Phosphorylation and Cytotoxicity in Autonomous Cancer Cells Cancer Res., July 1, 2000; 60(13): 3425 - 3428. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Sgadari, E. Toschi, C. Palladino, G. Barillari, D. Carlei, A. Cereseto, C. Ciccolella, R. Yarchoan, P. Monini, M. Sturzl, et al. Mechanism of Paclitaxel Activity in Kaposi's Sarcoma J. Immunol., July 1, 2000; 165(1): 509 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Miller, L. M. Krug, K. K. Ng, B. Pizzo, W. Perez, R. T. Heelan, and M. G. Kris Phase II Trial of Docetaxel and Vinorelbine in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., March 13, 2000; 18(6): 1346 - 1350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Miayake, A. Tolcher, and M. E. Gleave Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides J Natl Cancer Inst, January 5, 2000; 92(1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hopfner, M. Mousli, J.-M. Jeltsch, A. Voulgaris, Y. Lutz, C. Marin, J.-P. Bellocq, P. Oudet, and C. Bronner ICBP90, a Novel Human CCAAT Binding Protein, Involved in the Regulation of Topoisomerase II{{alpha}} Expression Cancer Res., January 1, 2000; 60(1): 121 - 128. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Chamoux Involvement of the Angiotensin II Type 2 Receptor in Apoptosis during Human Fetal Adrenal Gland Development J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4722 - 4730. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. FADEEL, B. ZHIVOTOVSKY, and S. ORRENIUS All along the watchtower: on the regulation of apoptosis regulators FASEB J, October 1, 1999; 13(13): 1647 - 1657. [Abstract] [Full Text]
|
|
